Esbriet Launches in Top 5 EU Countries
Based on InterMune's anticipated EU country reimbursement timelines, the company currently plans to launch Esbriet in France, Spain and Italy during the second quarter of 2012 and in the United Kingdom in October of 2012 (previously third quarter).
The company announced that on January 5 it submitted its comprehensive response to the IQWiG report in Germany and that it expects a decision by the German Federal Joint Committee (G-BA) by March 15, 2012 regarding the additional benefit that Esbriet provides. On today's teleconference, Prof. Dr. Christian Dierks, partner in the law firm of Dierks and Bohle, regulatory and reimbursement consultant to InterMune and a specialist in German drug reimbursement law will join the call to answer questions related to the German pricing and reimbursement process.
Esbriet Launches in Mid-Sized EU Countries
In addition to launches in the Top 5 EU countries, the company expects to launch in Austria, Denmark, Ireland and Norway in the first half of 2012, and in Belgium, the Netherlands, Finland and Sweden in the second half of the year.
InterMune estimates that the number of IPF patients is approximately 6,000 in the Benelux Region; approximately 5,500 in the Nordic Region; approximately 1,800 in Austria and about 1,000 in Ireland.
InterMune today reported that Denmark is the fourth country in which the company has obtained a published price for Esbriet, in addition to Germany, Norway and
|SOURCE InterMune, Inc.|
Copyright©2010 PR Newswire.
All rights reserved